Close Menu

Editor's Pick

Multinational nephrology firm Fresenius Medical Care eventually wants as many as 200,000 samples in its registry and aims to sequence 20,000 patients this year.

By extending Terra to the Microsoft Azure cloud, the Broad and Verily Life Sciences hope to facilitate better data sharing, analysis, and reuse.

The decision comes amid a general slowdown in the market, yet also showcases the continued appeal of ancestry-related applications.

Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.

Some tests that detect multiple SARS-CoV-2 genes are serendipitously signaling new viral variants while still effectively detecting infections.

Some core labs are expecting long waitlists in 2021 as PacBio's HiFi reads draw interest from researchers looking to put together whole genomes.

Over the next year or so, the investigators plan to sequence the genomes of 3,000 patients with cancer, heart disease, diabetes, or neurological disorders.

The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated. 

The two new tests, which have the capability to quantify a patient's viral load, have been designed without external RNA extraction or amplification steps.

The firm claims a rapid isothermal test has an LoD of 20 viral copies per milliliter while a saliva-based PCR test has an LoD of 2 copies per milliliter.

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.